Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer. Issue 10 (17th August 2020)

• Record Type: Journal Article
• Authors: Liu, Kai; Hu, Huiying; Jiang, Huanyu; Liu, Chenglei; Zhang, Haidong; Gong, Shanchun; Wei, Dongmin; Yu, Zhenkun
• Is Part Of: Molecular carcinogenesis. Volume 59:Issue 10(2020)
• Page Start: 1147
• Page End: 1158
• Publication Date: 2020-08-17
• Subjects: cetuximab resistance -- HNSCC -- KRAS/MEK -- malignant progression -- SPP1; Carcinogenesis -- Molecular aspects -- Periodicals; 616.994071
• DOI: 10.1002/mc.23245
• Languages: English
• ISSNs: 0899-1987

Abstract

Abstract: Acquired resistance is a barrier to cetuximab efficacy in patients with head and neck squamous cell carcinoma (HNSCC). Secreted phosphoprotein 1 (SPP1) is involved in various biological processes, including immune responses, cancer progression, and prognosis in many cancers, while little is known in HNSCC. Bioinformatics methods were used to identify candidate genes and further in vivo and in vitro experiments were performed to examine and validate the function of SPP1. We found that SPP1 was upregulated and has been found to have an oncogenic role in HNSCC. We further confirmed that overexpression of SPP1 affected proliferation, migration, invasion, and survival, and inhibited apoptosis, whereas silencing of SPP1 yielded opposite results to those of SPP1 overexpression. In addition, activation of the KRAS/MEK pathway contributed to the SPP1‐induced malignant progression of HNSCC and resistance to cetuximab. Furthermore, SPP1 knockdown or an MEK inhibitor overcame this cetuximab‐resistance pattern. Taken together, our findings for the first time identify the role of SPP1 in tumor promotion, prognostic prediction, and potential therapeutic targeting, as well as resistance to cetuximab in HNSCC.